Supplementary Data 1. The following antibodies were used in this study.

Stressgen Biotechnologies (Victoria, BC, Canada) Anti-HSP72 antibody: SPA-810 Santa Cruz Biotechnology (Santa Cruz, CA) Anti-insulin antibody: sc-9168 Anti-nuclear factor of activated T-cell (NFAT) c1antibody: sc-7294 Anti-glucose transporter (GLUT) 2 antibody: sc-9117 Anti-BiP (GRP78) antibody: sc-1050 Anti-C/EBP homologous protein (CHOP) (GADD153) antibody: sc-575 8-Hydroxy-2'-deoxyguanosine (8-OHdG) antibody: sc-66036 XBP-1antibody: sc-7160 Anti-actin antibody: sc-1615 Cell Signaling Technology Inc. (Beverly, MA) Anti-forkhead box O1 (FOXO1) antibody: #9462 Anti-phospho-c-jun N-terminal kinase (JNK) antibody: #9251 Anti-JNK antibody: #9252 Anti-nuclear factor-kappa B (NF-κB) p65 antibody: #4764 Anti-cleaved-caspase-3 antibody: #9661 Anti-phospho-AMPKa: #2535 Anti-AMPKa: #2532 Chemicon International Inc. (Billerica, MA) Anti-pancreatic and duodenal homeobox (PDX)-1 antibody: AB3243 α-tubulin antibody: #05-829 Upstate Biotechnology (Lake Placid, NY) Anti-insulin receptor substrate (IRS)-2 antibody: 06-506 Biorbyt (Riverside, UK) Anti-Annexin V antibody: orb18007

Supplementary Data 2. Primer sequences for quantitative real time RT-PCR.

insulin-2 FW; 5'-GCTCTCTACCTGGTGTGTGG-3', insulin-2 RV; 5'-GTTTTATTCATTGCAGAGGG-3', Hsp72 FW; 5'-TGGTGCTGACGAAGATGAAG-3', Hsp72 RV; 5'-AGGTCGAAGATGAGCACGTT-3', PDX-1 FW; 5'-GAAATCCACCAAAGCTCACG-3', PDX-1 RV; 5'-TTCAACATCACTGCCAGCTC-3', BiP FW; 5'-ATCGGACGCACTTGGAATGAC-3', BiP RV; 5'-TTCCCAAATACGCCTCAGCAG-3', CHOP FW; 5'-CATACACCACCACACCTGAAAG-3', CHOP RV; 5'-CGTTACACCACCACACCTGAAAG-3', β -actin-FW; 5'-CGTAAAGACCTCTATGCCAA-3', β -actin-RV: 5'-AGCCATGCCAATGTTGTCTC-3'.


To assess the specificity of the amplified PCR products, a melting curve analysis was performed after the last cycle.

Supplementary Figure 1. Insulin secretion capacity in MIN6 cells.

A: MIN 6 cells were incubated with 400μ M palmitate for 24hr, then sham, MES, HS or HS+MES treatment were performed for 10min. After 6 and 10 hrs of these treatments, insulin concentrations in culture medium were measured by ELISA.

B: MIN 6 cells were incubated with 400μ M palmitate for 24hr, then sham or HS+MES treatment were performed for 10min. After 0, 1 and 3 hrs of these treatments, cell lysates were isolated, and AMPK and phospho-AMPK levels were determined by Western blot.

*p < 0.05, **p < 0.01 vs. sham-treated control.




Supplementary Figure 1.

Supplementary Figure 2. Molecular markers of pancreatic β -cell integrity and function.

Immunohistochemical analysis of molecular markers associated with pancreatic β -cell integrity and function (a and b; NFAT/insulin, c and d; GLUT2, e and f; IRS-2).

GLUT2 and IRS-2 protein were determined by Western blotting, and the expression levels were corrected using internal control, α -tubulin.

*p < 0.05, **p < 0.01, N.S. vs. sham-treated wt control. #p < 0.05 vs. indicated group.




Supplementary Figure 3. Molecular markers of apoptotic signal, inflammation and oxidative stress in pancreatic β -cells.

Immunohistochemical analysis of molecular markers associated with apoptosis (A: a and b; Cleaved caspase-3, c and d; Annexin-V), inflammation (B: a and b; NF-κB) and oxidative stress (B: c and d; 8-OHdG) in sham-treated db/db and HS+MES treated db/db islets.

Cleaved caspase-3 protein were determined by Western blotting, and the expression levels were corrected using internal control, α -tubulin.

**p < 0.01, N.S. vs. sham-treated wt control. #p < 0.05 vs. indicated group.



Supplementary Figure 3.